These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11295 related articles for article (PubMed ID: 15318702)

  • 21. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings.
    Tartour E; Mehtali M; Sastre-Garau X; Joyeux I; Mathiot C; Pleau JM; Squiban P; Rochlitz C; Courtney M; Jantscheff P; Herrmann R; Pouillart P; Fridman WH; Dorval T
    Br J Cancer; 2000 Dec; 83(11):1454-61. PubMed ID: 11076653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
    J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
    van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
    Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors.
    Moiseyenko VM; Danilov AO; Baldueva IA; Danilova AB; Tyukavina NV; Larin SS; Kiselev SL; Orlova RV; Anisimov VV; Semenova AI; Shchekina LA; Gafton GI; Kochnev VA; Barchuk AS; Kanaev SV; Hanson KP; Georgiev GP
    Ann Oncol; 2005 Jan; 16(1):162-8. PubMed ID: 15598955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell immunotherapy for stage IV melanoma.
    O'Rourke MG; Johnson MK; Lanagan CM; See JL; O'Connor LE; Slater GJ; Thomas D; Lopez JA; Martinez NR; Ellem KA; Schmidt CW
    Melanoma Res; 2007 Oct; 17(5):316-22. PubMed ID: 17885587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.
    Nemunaitis J; Nemunaitis M; Senzer N; Snitz P; Bedell C; Kumar P; Pappen B; Maples PB; Shawler D; Fakhrai H
    Cancer Gene Ther; 2009 Aug; 16(8):620-4. PubMed ID: 19287371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
    J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.
    Tait DL; Obermiller PS; Hatmaker AR; Redlin-Frazier S; Holt JT
    Clin Cancer Res; 1999 Jul; 5(7):1708-14. PubMed ID: 10430073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes.
    Matsumoto K; Kubo H; Murata H; Uhara H; Takata M; Shibata S; Yasue S; Sakakibara A; Tomita Y; Kageshita T; Kawakami Y; Mizuno M; Yoshida J; Saida T
    Jpn J Clin Oncol; 2008 Dec; 38(12):849-56. PubMed ID: 18945721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xenovaccinotherapy for melanoma.
    Seledtsov VI; Shishkov AA; Surovtseva MA; Samarin DM; Seledtsova GV; Niza NA; Seledtsov DV
    Eur J Dermatol; 2006; 16(6):655-61. PubMed ID: 17229606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma.
    Gonzalez R; Hutchins L; Nemunaitis J; Atkins M; Schwarzenberger PO
    Melanoma Res; 2006 Dec; 16(6):521-6. PubMed ID: 17119453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
    Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S
    J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic gene-modified tumour cells in metastatic kidney cancer. Preliminary report.
    Pizza G; De Vinci C; Lo Conte G; Mazzuca A; Corrado G; Menniti D; Benati A; Romagnoli P; Fornarola V; Busutti L; Palareti A; Capanna R; Di Maio V; Ratini S; Gulino A; Vacca A; Melchiorri L; Ferrari M; Boriani S; Baricordi RO
    Folia Biol (Praha); 2003; 49(4):147-59. PubMed ID: 12971584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-specific dendritic-cell vaccines for metastatic melanoma.
    Dillman RO; Selvan SR; Schiltz PM
    N Engl J Med; 2006 Sep; 355(11):1179-81. PubMed ID: 16971731
    [No Abstract]   [Full Text] [Related]  

  • 39. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
    Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 565.